Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 11

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 11
---
2)(3) |     | II    |     |  67 |     | Class II Director                                         |     |     2021 |     |    2025 |     |       2028 |
| Continuing Directors               |     |       |     |     |     |                                                           |     |          |     |         |     |            |
| Kirsten Flowers(1)                 |     | I     |     |  50 |     | Class I Director                                          |     |     2022 |     |    2027 |     |          — |
| Carol Gallagher, Pharm.D.(3)       |     | I     |     |  60 |     | Class I Director                                          |     |     2022 |     |    2027 |     |          — |
| David H. Mack, Ph.D.               |     | III   |     |  63 |     | President, Chief Executive Officer and Class III Director |     |     2013 |     |    2026 |     |          — |
| Richard Heyman, Ph.D.(1)(2)(3)     |     | III   |     |  67 |     | Chairperson and Class III Director                        |     |     2020 |     |    2026 |     |          — |
| Laurie Stelzer(1)(2)               |     | III   |     |  57 |     | Class III Director                                        |     |     2020 |     |    2026 |     |          — |

| (1) | Member of the audit committee |

| (2) | Member of the compensation committee |

| (3) | Member of the nominating and corporate governance committee |

Nominees for Election to a Three-Year Term Ending at the 2028 Annual Meeting Arnold Levine, Ph.D. has served as a member of our board of directors since June 2013. Since 2011, Dr. Levine has served as a Professor Emeritus at The Simons Center for Systems Biology at the Institute for Advanced Study in Princeton, New Jersey. Dr. Levine trained as a Postdoctoral Fellow at California Institute of Technology in the laboratory of Robert Sinsheimer. Dr. Levine is a widely acclaimed leader in cancer research. Dr. Levine currently serves on the board of directors of GeneCentric Therapeutics, a private biomarker producer, and serves on the scientific advisory board of Chugai Pharmabody Research,